Dupilumab is the first investigational biologic to significantly improve lung function in COPD patients
Dupilumab (Dupixent; Sanofi) is the first and only investigational biologic to significantly improve lung function at 12 and 52 weeks and significantly reduce severe acute exacerbations compared with placebo in adults with chronic obstructive pulmonary disease (COPD), according to the authors. presented a positive Phase 3 best outcome at the 2023 American Thoracic Society (ATS) … Read more